Intervention Protocol

Chelation for autism spectrum disorder (ASD)

  1. Stephen James1,*,
  2. Katrina Williams2,3,4,
  3. Natalie Silove5,
  4. Shawn W Stevenson6

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 11 OCT 2013

DOI: 10.1002/14651858.CD010766


How to Cite

James S, Williams K, Silove N, Stevenson SW. Chelation for autism spectrum disorder (ASD) (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010766. DOI: 10.1002/14651858.CD010766.

Author Information

  1. 1

    Arizona State University, School of Social Work, Phoenix, Arizona, USA

  2. 2

    University of Melbourne, Department of Paediatrics, Parkville, Victoria, Australia

  3. 3

    Royal Children's Hospital, Department of Developmental Medicine, Parkville, Victoria, Australia

  4. 4

    Murdoch Childrens Research Institute, Parkville, Victoria, Australia

  5. 5

    The Children's Hospital at Westmead, Child Development Unit, Westmead, New South Wales, Australia

  6. 6

    University of Melbourne, The Royal Children's Hospital, Department of Paediatrics, Parkville, Victoria, Australia

*Stephen James, School of Social Work, Arizona State University, 411 N. Central Avenue, Suite 800, Phoenix, Arizona, 85004-0689, USA. stephen.james@green.oxon.org. stephen.nicholas.james@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 11 OCT 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the potential benefits and adverse effects of chelation for ASD symptomatology.